

Stefanie Derer

Ph.D. senior scientist

Dr. Derer is trained in ecotrophology with the focus on nutritional science. She performed her Ph.D. thesis in the field of inflammatory bowel disease and received her Ph.D. in molecular biology in 2009. As a post-doctoral fellow, she moved into the research field of “oncology & hematology” at the University Hospital Schleswig-Holstein (UKSH) Campus Kiel, where she has been specialized on oncogenic KRAS mutations as well as on the epidermal growth factor receptor (EGFR) in antibody-based therapy of colorectal carcinoma patients. In 2015 Dr. Derer joined the Campus Lübeck of the UKSH. Since 2016, she is heading the laboratory and the group “Molecular Gastroenterology” in the Institute of Nutritional Medicine. She recently defined the term Nutri-Inflammation to highlight the potential of nutrition to constantly promote intestinal inflammation and hence lifestyle-associated colorectal cancer. Dr. Derer is a member of the German Crohn’s & Colitis Foundation (DCCV) and the German Society of Nutritional Medicine (DGEM).

Contact

stefanie.Derer@uni-luebeck.de

Main publications (since 2017)

1. Raschdorf, A., A. Sünderhauf, K. Skibbe, B. Ghebrehiwet, E.I. Peerschke, C. Sina, and S. Derer. (2021). Heterozygous P32/C1QBP/HABP1 Polymorphism rs56014026 Reduces Mitochondrial Oxidative Phosphorylation and Is Expressed in Low-grade Colorectal Carcinomas. *Front Oncol*, 10:631592.
2. Sünderhauf, A., M. Hicken, H. Schlichting, K. Skibbe, M. Ragab, A. Raschdorf, M. Hirose, H. Schaffler, A. Bokemeyer, D. Bettenworth, A.G. Savitt, S. Perner, S. Ibrahim, E.L. Peerschke, B. Ghebrehiwet, S. Derer[#], and C. Sina[#]. (2021). Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. *Cell Mol Gastroenterol Hepatol*, doi: 10.1016/j.jcmgh.2021.01.017
3. Sünderhauf, A., A. Raschdorf, M. Hicken, H. Schlichting, F. Fetzter, A.K. Brethack, S. Perner, C. Kemper, B. Ghebrehiwet, C. Sina, and S. Derer. (2020). GC1qR Cleavage by Caspase-1 Drives Aerobic Glycolysis in Tumor Cells. *Front Oncol*, **10**: p. 575854.
4. Sünderhauf, A., R. Pagel, A. Kunstner, A.E. Wagner, J. Rupp, S.M. Ibrahim, S. Derer[#], and C. Sina[#]. (2020). Saccharin Supplementation Inhibits Bacterial Growth and Reduces Experimental Colitis in Mice. *Nutrients*, **12**(4).
5. Derer, S.[§], A.K. Brethack[§], C. Pietsch, S.T. Jendrek, T. Nitzsche, A. Bokemeyer, J.R. Hov, H. Schäffler, D. Bettenworth, G.A. Grassl, and C. Sina. (2020). Inflammatory Bowel Disease-associated GP2 Autoantibodies Inhibit Mucosal Immune Response to Adherent-invasive Bacteria. *Inflamm Bowel Dis*, **26**(12): p. 1856-1868.

6. Preisker, S., A.K. Brethack, A. Bokemeyer, D. Bettenworth, C. Sina, and S. Derer. (2019). Crohn's Disease Patients in Remission Display an Enhanced Intestinal IgM⁽⁺⁾ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System. *Cells*, **8**(1).
7. Sina, C., C. Kemper, and S. Derer. (2018). The intestinal complement system in inflammatory bowel disease: Shaping intestinal barrier function. *Semin Immunol*, **37**: p. 66-73.
8. Sünderhauf, A. [§], K. Skibbe[§], S. Preisker, K. Ebbert, A. Verschoor, C.M. Karsten, C. Kemper, M. Huber-Lang, M. Basic, A. Bleich, J. Buning, K. Fellermann, C. Sina, and S. Derer. (2017). Regulation of epithelial cell expressed C3 in the intestine - Relevance for the pathophysiology of inflammatory bowel disease? *Mol Immunol*, **90**: p. 227-238.
9. Pagel, R., F. Bär, T. Schröder, A. Sünderhauf, A. Künstner, S.M. Ibrahim, S.E. Autenrieth, K. Kalies, P. König, A.H. Tsang, D. Bettenworth, S. Divanovic, H. Lehnert, K. Fellermann, H. Oster, S. Derer[#], and C. Sina[#]. (2017). Circadian rhythm disruption impairs tissue homeostasis and exacerbates chronic inflammation in the intestine. *FASEB J*, **31**(11): p. 4707-4719.
10. Jendrek, S.T., D. Gotthardt, T. Nitzsche, L. Widmann, T. Korf, M.A. Michaels, K.H. Weiss, E. Liaskou, M. Vesterhus, T.H. Karlsen, S. Mindorf, P. Schemmer, F. Bar, B. Teegen, T. Schroder, M. Ehlers, C.M. Hammers, L. Komorowski, H. Lehnert, K. Fellermann, S. Derer, J.R. Hov, and C. Sina. (2017). Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. *Gut*, **66**(1): p. 137-144.

[§] shared first authorship

[#] shared senior authorship